Company intelligence / Profile preview

Jieke (Tianjin) Biomedical

Tianjin, Tianjin, China

Ownership: Private
Employees: ~200
Development stage: Other

Overview

Jieke (Tianjin) Biomedical is a Chinese biotechnology company focused on the development and commercialization of high-quality biosimilars and innovative therapeutic antibodies. Based in the Tianjin Economic-Technological Development Area (TEDA), the company operates a large-scale mammalian cell culture facility designed to meet international GMP standards. Its pipeline primarily targets oncology and autoimmune diseases, with several programs having reached advanced clinical stages. Jieke aims to provide affordable biologic treatments to the Chinese market by leveraging its integrated R&D and manufacturing capabilities.

Therapeutic areas: OncologyImmunologyOphthalmologyDermatology
Modalities: Monoclonal antibodyRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Jieke (Tianjin) Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jieke (Tianjin) Biomedical.

Explore the full profile